Cardiovascular

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio has announced a private placement agreement valued at up to $250m, including $150m of committed capital intended to support the development and potential US Food and Drug Administration (FDA) approval of seralutinib.

FDA grants fast track designation for HAYA Therapeutics’ HTX-001

HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.

Affinia Therapeutics receives FDA orphan drug designation for AFTX-201

Affinia Therapeutics has received the US Food and Drug Administration (FDA) orphan drug designation for AFTX-201, a treatment in development for BAG3-associated dilated cardiomyopathy (DCM).

Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis

Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause of heart failure.

Cytokinetics receives FDA approval for MYQORZO tablets for oHCM

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to enhance functional capacity and symptoms.

FDA expands Amgen’s Repatha use to adults at risk of cardiovascular events

The US Food and Drug Administration (FDA) has expanded the use of Amgen’s Repatha (evolocumab) to include adults who are at high risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C).

Camurus and Eli Lilly collaborate on long-acting incretin products

Camurus and Eli Lilly have signed a partnership and license agreement focused on long-acting incretin products to improve cardiometabolic health.

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.